BOSTON LIFE SCIENCES (BLSI) Boston Life Sciences develops diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE® molecular imaging agent is in Phase 3 clinical trials for the diagnosis of Parkinson's Disease (PD) and Phase 2 clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). CENTHRIN®), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. The drug has reported positive interim results in a Phase 1/2a  clinical trial. Research and pre-clinical programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD.

BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston.